Xolair gets black box labeling

Share this article:

The FDA has announced new "black box" labeling for Genentech's Xolair (omalizumab) to address the risk of anaphylaxis in patients using the asthma drug.

The new labeling, the FDA’s strictest, indicates that patient reports following the drug's approval in 2003 through 2006 noted cases of anaphylaxis were seen in roughly two out of 1000 patients.

Genentech collaborates with Novartis on the marketing of Xolair, which had $425 million in global sales last year.


 

Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.